Oral ponesimod for psoriasis compared to other investigational therapies
- PMID: 28329623
Oral ponesimod for psoriasis compared to other investigational therapies
Abstract
Oral ponesimod is a new therapy for the treatment of moderate-to-severe plaque psoriasis. Vaclavkova et al conducted a phase 2 trial that demonstrated moderate efficacy of ponesimod in the treatment of psoriasis. Here we discuss various biologic agents with alternative mechanisms of action, that have demonstrated superior efficacy in psoriasis, and call into question the risks versus benefits of ponesimod therapy.
Comment on
-
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5. Epub 2014 Aug 10. Lancet. 2014. PMID: 25127208 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous